Healio Advancing DME Treatment Through Clinical Biomarkers and Extended Dosing Therapies

Key Features

Diabetic macular edema (DME) remains a leading a cause of vision loss in working-age and older adults worldwide. Intravitreal anti-vascular endothelial growth factor (VEGF) therapies have revolutionized the management of patients with DME. However, busy work schedules and multiple diabetes-related healthcare appointments often lead to loss to follow-up and treatment fatigue. The integration into practice of sustained delivery devices or therapies that offer longer duration of action provide the potential to significantly reduce treatment frequency while enhancing visual acuity outcomes. Biomarkers of vascular instability should be considered to help guide treatment decisions and monitor disease control. In this CE activity, experts in the field discuss novel biomarkers that can guide early clinical decision-making for enhanced visual outcomes; assess targeted therapies and their impact on blood vessel stability and macular leakage; and provide guidance for durable treatment selection for patients with DME based on the latest clinical evidence.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Recognize the role of novel biomarkers that can be used to guide early clinical decision-making for enhanced visual outcomes for patients with DME.
• Summarize the latest evidence regarding the impact of dual-targeted options on blood vessel stability and macular leakage.
• Select treatment for patients with DME based on the latest clinical evidence.

Target Audience

The intended audience for this activity is retina specialists and ophthalmologists involved in the management of patients with DME.

Additional credit info

In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.